Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-05-23
1997-11-11
Eisenschenk, Frank C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
536 234, 4351721, 435 711, 43524027, 435183, C07K 1900, C07H 2104
Patent
active
056865791
ABSTRACT:
A recombinant chimeric polypeptide is produced that contains a biologically active entity and a binding entity, that displays biologically active and is inactivation resistant. The biologically active entity corresponds, for example, to an enzyme and the binding entity corresponds, for example, to an antibody. The entities interact to form a structure analagous to an antibody-antigen complex. Thus, the inactivation-resistant complex displays prolonged activity under conditions characterized by disrupting temperature, the presence of a proteolytic enzyme, disrupting pH, the presence of an oxidizing agent and/or the presence of an alcohol, among others.
REFERENCES:
patent: 4059685 (1977-11-01), Johnson et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4704692 (1987-11-01), Ladner
M. G. Rosenblum et al., "Modification of Human Leukocyte Interferon Pharmacology with a Monoclonal Antibody", Cancer Research, 45: 2421-2424 (Jun. 1985).
G. T. Davis et al., "Single Chain Antibody (SCA) Encoding Genes: One-Step Construction and Expression in Eukarytic Cells", Bio/Technology, 9: 165-169 (Feb. 1991).
M. Ramjeesingh, et al., "Monoclonal Antibodies Can Protect.sub.L -Asparaginase Against Inactivation by Trypsin", Bio/Technology, 10: 442-445 (Apr. 1992).
N. Zyk, "Modification of .sub.L -Asparaginase EC-.sub.2 by Honologous Antibodies", Biochimica et Biophysica Acta, 302: 420-428 (1973).
R. Jemmerson et al., "Monoclonal Antibodies Block the Trypsin Cleavage Site on Human Placental Alkaline Phosphatase", FEBS LETTERS, 173(2): 357-359 (Aug. 1984).
F. A. Green, "Phospholipid Requirement for Rh Antigenic Activity", The Journal of Biological Chemistry, 243(20): 5519-5524 (1968).
F. A. Green, "The Mode of Attenuation of Erythrocyte Membrane Rh.sub.0 (D) Antigen Activity by 5.5'-Dithiobis-(2-Nitrobenzoic Acid) and Protection Against Loss of Activity . . . ", Molecular Immunology, 20(7) 769-755 (1983).
F. Melchers et al., "Enhancing Stability Against Heat Denaturation of E. coli Wild Type and Mutant .beta.-Galactosidase in the Presence of Specific . . . ", Biochem. and Biophys. Res. Comm., 40(3): 570-575 (1970).
W. P. Levy et al., "Amino Acid Sequence of a Human Leukocyte Interferon", Proc. Natl. Acad. Sci. USA, 75(10): 6186-6190 (Oct. 1981).
"Albumin Complexes May Further Enzyme Therapy", Chem. Eng. News, 19-21 (Sep. 30, 1985).
Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242: 423-426 (1988).
Ben-Yoseph et al. "Antibody-Mediated Thermal Stabilization of Human Hexosaminidases", Immunochemistry, 12: 221-226 (1975).
Sandhu, Crit. Rev. Biotech, 12:437, 1992.
Wilhelm et al., Crit. Rev. Eukaryotic Gene Express., 2:111, 1992.
Ramjeesingh Mohabir
Rothstein Aser
Shami Ezekiel Y.
Eisenschenk Frank C.
Hybrisens, Ltd.
LandOfFree
Use of antibody/antigen interactions to protect biologically act does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antibody/antigen interactions to protect biologically act, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antibody/antigen interactions to protect biologically act will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1230288